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Plasma Adiponectin Concentration Is Associated With
Skeletal Muscle Insulin Receptor Tyrosine
Phosphorylation, and Low Plasma Concentration
Precedes a Decrease in Whole-Body Insulin Sensitivity
in Humans
Norbert Stefan,1 Barbora Vozarova,1 Tohru Funahashi,2 Yuji Matsuzawa,2 Christian Weyer,1
Robert S. Lindsay,1 Jack F. Youngren,3 Peter J. Havel,4 Richard E. Pratley,1 Clifton Bogardus,1
and P. Antonio Tataranni1
Adiponectin, the most abundant adipose-specific pro-
tein, has been found to be negatively associated with
degree of adiposity and positively associated with insu-
lin sensitivity in Pima Indians and other populations.
Moreover, adiponectin administration to rodents has been
shown to increase insulin-induced tyrosine phosphory-
lation of the insulin receptor (IR) and also increase
whole-body insulin sensitivity. To further characterize
the relationship between plasma adiponectin concentra-
tion and insulin sensitivity in humans, we examined 1)
the cross-sectional association between plasma adi-
ponectin concentration and skeletal muscle IR tyrosine
phosphorylation and 2) the prospective effect of plasma
adiponectin concentration at baseline on change in
insulin sensitivity. Fasting plasma adiponectin concen-
tration, body composition (hydrodensitometry or dual
energy X-ray absorptiometry), insulin sensitivity (insulin-
stimulated glucose disposal, hyperinsulinemic clamp),
and glucose tolerance (75-g oral glucose tolerance test)
were measured in 55 Pima Indians (47 men and 8 women,
aged 31  8 years, body fat 29  8% [mean  SD]; 50
with normal glucose tolerance, 3 with impaired glucose
tolerance, and 2 with diabetes). Group 1 (19 subjects)
underwent skeletal muscle biopsies for the measure-
ment of basal and insulin-stimulated tyrosine phosphor-
ylation of the IR (stimulated by 100 nmol/l insulin). The
fold increase after insulin stimulation was calculated as
the ratio between maximal and basal phosphorylation.
Group 2 (38 subjects) had follow-up measurements of
insulin-stimulated glucose disposal. Cross-sectionally,
plasma adiponectin concentration was positively associ-
ated with insulin-stimulated glucose disposal (r  0.58,
P < 0.0001) and negatively associated with percent
body fat (r  0.62, P < 0.0001) in the whole group. In
group 1 plasma adiponectin was negatively associated
with the basal (r  0.65, P  0.003) and positively
associated with the fold increase in IR tyrosine phos-
phorylation (r  0.69, P  0.001) before and after the
adjustment for percent body fat (r  0.58, P  0.01
and r  0.54, P  0.02, respectively). Longitudinally,
after adjustment for age, sex, and percent body fat, low
plasma adiponectin concentration at baseline was asso-
ciated with a decrease in insulin sensitivity (P  0.04).
In conclusion, our cross-sectional data suggest a role of
physiological concentration of fasting plasma adiponec-
tin in the regulation of skeletal muscle IR tyrosine
phosphorylation. Prospectively, low plasma adiponectin
concentration at baseline precedes a decrease in insulin
sensitivity. Our data indicate that adiponectin plays an
important role in regulation of insulin sensitivity in
humans. Diabetes 50:1884–1888, 2002
A dipose tissue serves not only as an energystorage organ, but also secretes hormones andmetabolites that are thought to regulate insulinsensitivity and energy metabolism (1,2). Adi-
ponectin, the most abundant adipose-specific protein, is
exclusively expressed in and secreted from adipose tissue
(3–5). Plasma adiponectin concentration is decreased in
individuals with obesity (4–6) and type 2 diabetes (7) and
is more closely related to whole-body insulin sensitivity
than to adiposity (8). In rhesus monkeys, plasma adiponec-
tin concentration has been shown to decrease in parallel
with increases in insulin sensitivity during the progression
to type 2 diabetes (9). Whereas these findings provide
circumstantial evidence that adiponectin may modulate
insulin sensitivity, more recent studies demonstrate that
administration of adiponectin to rodents increases insulin-
induced tyrosine phosphorylation of the insulin receptor
(IR) in skeletal muscle, resulting in improved glucose
From the 1Clinical Diabetes and Nutrition Section, National Institutes of
Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
Phoenix, Arizona; the 2Department of Internal Medicine and Molecular
Science, Graduate School of Medicine, Osaka University, Osaka, Japan; the
3Department of Medicine, Division of Diabetes and Endocrine Research,
Mount Zion Medical Center, University of California, San Francisco, Califor-
nia; and the 4Department of Nutrition, University of California, Davis, Califor-
nia.
Address correspondence and reprint requests to Norbert Stefan, Clinical
Diabetes and Nutrition Section, National Institutes of Health, 4212 N. 16th St.,
Rm. 5-41, Phoenix, AZ 85016. E-mail: nstefan@mail.nih.gov.
Received for publication 19 January 2002 and accepted in revised form 6
March 2002.
N.S. and B.V. contributed equally to this work.
T.F. and Y.M. were supported by the Japan Society for the Promotion of
Science and Education (JSP-RFTF 97L00801) and a grant from the Fuji
Foundation for Protein Research.
ELISA, enzyme-linked immunosorbent assay; EMBS, estimated metabolic
body size (fat – free mass  17.7 kg); IR, insulin receptor; IRS-1, IR
substrate-1; OGTT, oral glucose tolerance test.
1884 DIABETES, VOL. 50, JUNE 2002
tolerance in these animals (10). The role of adiponectin in
modulating insulin signaling in humans remains unknown.
In vivo insulin-mediated glucose disposal occurs primar-
ily in skeletal muscle (11). In Pima Indians, obesity and
insulin resistance are associated with impairments of
skeletal muscle IR tyrosine phosphorylation in response to
insulin (12). To further characterize the relationship be-
tween adiponectin and glucose/insulin metabolism in hu-
mans, we examined 1) the cross-sectional association
between plasma adiponectin concentration and skeletal
muscle IR tyrosine phosphorylation and 2) the prospective
association between plasma adiponectin concentration at
baseline and change in whole-body insulin sensitivity.
RESEARCH DESIGN AND METHODS
Subjects. A total of 55 Pima Indians (Table 1) who were participants in
ongoing studies of the pathogenesis of obesity and type 2 diabetes were
included in this analysis. Subjects for the present analysis were selected from
participants of a longitudinal study of the risk factors of obesity and type 2
diabetes and had been admitted to the metabolic ward for measurements
including muscle insulin-stimulated IR phosphorylation (12) and plasma
adiponectin (8). All subjects were between 18 and 50 years of age and were
nonsmokers at the time of the study. Except for two subjects with type 2
diabetes, all subjects were healthy according to a physical examination and
routine laboratory tests. Subjects were then invited back at approximately
annual intervals for repeated oral glucose tolerance tests (OGTTs) and, in a
subgroup of subjects, for repeated assessment of insulin sensitivity. The
protocol was approved by the Tribal Council of the Gila River Indian
Community and by the Institutional Review Board of the National Institute of
Diabetes and Digestive and Kidney Diseases, and all subjects provided written
informed consent before participation.
Cross-sectional analyses were carried out in all subjects (n 55) who were
characterized for plasma adiponectin concentration, glucose tolerance, per-
cent body fat, insulin sensitivity; in addition, a subgroup (group 1, n  19)
underwent muscle biopsies for measurement of skeletal muscle IR tyrosine
phosphorylation. Subjects included in this analysis represented a wide range
of glucose tolerance (14 normal glucose tolerant, 3 impaired glucose tolerant,
and 2 type 2 diabetic subjects, according to the 1997 American Diabetes
Association diagnostic criteria (13).
Prospective analyses were performed in a subgroup of subjects (group 2,
n  38) who were normal glucose tolerant at baseline, were nondiabetic at
follow-up, and had baseline measurements of plasma adiponectin concentra-
tion, percent body fat, 2-h glucose, insulin-stimulated glucose disposal, and
follow-up measurements of insulin-stimulated glucose disposal (group 2).
Methods. Subjects were admitted for 8–10 days to the National Institutes of
Health Clinical Research Unit in Phoenix, AZ, where they were fed a
weight-maintaining diet (50% of calories as carbohydrate, 30% as fat, and 20%
as protein) and abstained from strenuous exercise. After at least 3 days on the
diet, subjects underwent a series of tests for the assessment of body
composition, glucose tolerance, insulin sensitivity, and (in selected cases)
skeletal muscle biopsies.
Body composition was estimated by underwater weighing with determina-
tion of residual lung volume by helium dilution (14) or by total body
dual-energy X-ray absorptiometry (DPX-L; Lunar, Madison, WI) (15,16). Per-
cent body fat, fat mass, and fat-free mass were calculated as previously
described (17), and a conversion equation (16) was used to make measure-
ments comparable between the two methods.
After a 12-h overnight fast, subjects underwent a 75-g OGTT. Baseline
blood samples were drawn for the determination of fasting plasma glucose,
insulin, and adiponectin concentrations. Plasma glucose concentration was
determined by the glucose oxidase method (Beckman Instruments, Fullerton,
CA) in the fasting state and 2 h after glucose ingestion for the assessment of
glucose tolerance, according to the 1997 American Diabetes Association
diagnostic criteria (13). Plasma insulin concentration was determined by an
automated immunoassay (Access; Beckman Instruments). Blood samples for
the measurement of fasting plasma adiponectin concentration were drawn
with prechilled syringes, transferred into prechilled EDTA tubes, and imme-
diately placed on ice. All tubes were cold centrifuged (4°C) within several
minutes of collection and stored at –70°C until assayed at the Department of
Internal Medicine and Molecular Sciences, Osaka University, Osaka, Japan.
Fasting plasma adiponectin concentration was determined using a validated
sandwich enzyme-linked immunosorbent assay (ELISA) employing an adi-
ponectin-specific antibody (intra-assay and interassay coefficients of variation
3.3 and 7.4%, respectively).
Hyperinsulinemic-euglycemic glucose clamp. Insulin action was assessed
at physiological insulin concentrations during a hyperinsulinemic-euglycemic
glucose clamp as previously described (18,19). In brief, after an overnight fast,
a primed continuous intravenous insulin infusion was administered for 100
min at a constant rate of 40 mU  m2 body surface area  min1 leading to
steady-state plasma insulin concentrations. Plasma glucose concentration was
maintained at 5.5 mmol/l with a variable infusion of a 20% glucose solution.
The rate of total insulin-stimulated glucose disposal was calculated for the last
40 min of insulin infusion. The insulin-stimulated glucose disposal values were
additionally adjusted for endogenous glucose production (measured by a
primed [30-Ci] continuous [0.3 Ci/min] 3-3H-glucose infusion), steady-state
plasma glucose, and insulin concentration as previously described (18) and
were normalized to estimated metabolic body size (EMBS) (EMBS  fat-free
mass  17.7 kg).
IR tyrosine kinase activity. Percutaneous needle biopsies of the vastus
lateralis muscle were performed under local anesthesia (1% lidocaine) after a
12-h overnight fast and 2 days after the hyperinsulinemic-euglycemic glucose
clamp. Muscle samples were blotted dry, quick frozen in liquid nitrogen, and
stored at –70°C until analysis. To prepare soluble extracts of muscle tissue for
IR tyrosine phosphorylation measurements, 100–150 mg frozen tissue was
pulverized under liquid nitrogen, and the resultant powder was homogenized
in 0.75–1.5 ml buffer [20 mmol/l tris(hydroxymethyl) aminomethane (Tris), 5
mmol/l MgCl2, 1 mmol/l phenylmethylsulfonyl fluoride (PMSF), 2 mol/l
leupeptin, and 2 mol/l pepstatin, pH 8.7] at 4°C using a Polytron homogenizer
TABLE 1
Anthropometrical and metabolic characteristics for subjects included in the analyses
All Group 1 Group 2
n  55
(47 men and 8 women)
n  19
(17 men and 2 women)
n  38
(32 men and 6 women)
Basal Follow-up P*
Age (years) 31 8 32 8 28  7 31 7
Height (cm) 171 7 172 8 170  7 170 7 0.65
Weight (kg) 95 24 105 23 92 23 98 25 0.001
Body fat (%) 29 8 32 8 29  8 30 6 0.05
Fasting glucose (mmol/l) 4.7 0.6 4.8 0.7 4.6 0.4 4.8 0.4 0.01
2-h glucose (mmol/l) 5.8 1.9 6.4 2.5 5.4 1.3 6.5 1.6 0.001
Fasting insulin (pmol/l) 238 122 275 146 217 104 244 97 0.06
2-h insulin (pmol/l) 1,014 1,158 1,428 1,620 771 751 1,218 1,152 0.05
Insulin-stimulated glucose disposal
(mg  kg EMBS1  min1) 2.97 1.6 279 1.48 3.10 1.63 2.7 0.99 0.05
Adiponectin (g/ml) 6.87  2.74 5.47 1.83 7.58 2.80 — —
Data are means  SE. Group 1: subjects who underwent skeletal muscle biopsies; group 2: subjects with baseline and follow-up
measurements of insulin-stimulated glucose disposal. *Paired t test between basal and follow-up.
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(Kinematica, Lucerne, Switzerland) for 10 s at a setting of 9. Triton X-100 was
added to a final concentration of 1%, and the homogenate was solubilized for
60 min at 4°C. The material was then centrifuged at 100,000g for 60 min at 4°C
and the supernatant collected and stored at 70°C. Muscle IR tyrosine
phosphorylation was determined using an ELISA (12,20). Ninety-six–well
microtiter plates were coated with 0.2 g anti-IR antibody MA-20, 100 l
solubilized muscle extract (600 pg IR/ml) was added to each well, and
receptors were allowed to bind overnight at 4°C. The following morning,
receptors were preincubated for 15 min at 22°C in 80 l assay buffer without
or with insulin (final concentration 100 nmol/l). The phosphorylation reaction
was started by adding 20 l of a 50-mol/l ATP solution and allowed to
continue for 60 min at 22°C. The amount of tyrosine phosphorylated IR was
quantified with biotinylated anti-phosphotyrosine antibody, to which peroxi-
dase-conjugated streptavidin was added. The absorption at 450 nm of each
well was measured in a microtiter plate reader (DuPont NEN, Boston, MA).
Basal and maximal IR tyrosine phosphorylation were measured at 0 and 100
nmol/l insulin, respectively. The fold increase after insulin stimulation was
calculated as the ratio between maximal and basal phosphorylation. As
previously reported, this measure is highly correlated to the ability of the IRs
to act as a tyrosine kinase and to phosphorylate exogenous substrates, such
as the artificial substrate poly-(Glu,Tyr), after adding ATP (12).
Statistical analyses. Statistical analyses were performed using the software
of the SAS Institute (Cary, NC). Results are given as means  SD. Fasting
plasma adiponectin and insulin-stimulated glucose disposal were logarithmi-
cally transformed to approximate a normal distribution. Differences between
anthropometrical and metabolic characteristics at baseline and follow-up
were assessed by Student’s t test.
In cross-sectional analyses, relationships between plasma adiponectin
concentration, percent body fat, insulin-stimulated glucose disposal, and IR
tyrosine phosphorylation were examined by calculation of Pearson’s correla-
tion coefficients. Partial correlation was used to examine the relationships
between plasma adiponectin and phosphorylation status, independent of
percent body fat.
In prospective analyses, the predictive effect of plasma adiponectin con-
centration at baseline on change (follow-up adjusted for baseline) in insulin-
stimulated glucose disposal was evaluated using multiple linear regression
models. Models were adjusted for sex, follow-up age, change in percent body
fat, and time of follow-up.
RESULTS
The anthropometrical and metabolic characteristics for
the subjects included in the cross-sectional and longitudi-
nal analyses are summarized in Table 1.
Cross-sectional analysis. Plasma adiponectin concen-
tration was positively associated with insulin-stimulated
glucose disposal (r  0.58, P  0.0001) and negatively
associated with percent body fat (r  0.62, P  0.0001)
in 55 subjects. In group 1 (n  19), plasma adiponectin
concentration was negatively associated with basal (r 
0.65, P  0.003) and positively associated with the fold
increase in skeletal muscle IR tyrosine phosphorylation
(r  0.69, P  0.001) (Fig. 1) before and after adjustment
for percent body fat in a partial correlation (r  0.58,
P  0.01 and r  0.54, P  0.02, respectively). Plasma
adiponectin concentration was also negatively associated
with basal skeletal muscle IR tyrosine phosphorylation
after adjustment for percent body fat and fasting plasma
insulin concentration (r  0.55, P  0.02).
Prospective analysis. Low plasma adiponectin concen-
tration at baseline was associated with a decrease in
insulin-stimulated glucose disposal after adjustment for
sex, age at follow-up, time of follow-up, and change in
percent body fat (P  0.04) (Table 2 and Fig. 2).
DISCUSSION
In the present study, we found that a low fasting plasma
adiponectin concentration was cross-sectionally associ-
ated with a high basal and low insulin-stimulated skeletal
muscle IR tyrosine phosphorylation and prospectively
associated with a decrease in insulin sensitivity. Our
results are consistent with the notion that adiponectin
plays a role in insulin sensitivity in humans.
We have previously established that adiponectin is
associated with whole-body insulin sensitivity in humans
(8). We now show that low plasma adiponectin concentra-
tion is associated with a high basal and decreased insulin-
stimulated tyrosine phosphorylation of the IR in skeletal
muscle, which is consistent with experimental observa-
tions in rodents (10). A high basal level of phosphorylation
of the IR at tyrosine residues has been shown to be
associated with hyperinsulinemia in the sand rat model of
type 2 diabetes (21). In humans, little is known about the
relationships between basal IR tyrosine phosphorylation
and insulin sensitivity. Nevertheless, a high basal phos-
phorylation of IR substrate-1 (IRS-1), which is down-
stream of tyrosine phosphorylation of the IR (22), has
been associated with insulin resistance and type 2 diabetes
(23,24). Increased basal phosphorylation of IRS-1 would
FIG. 1. Relationship between fasting plasma adiponectin concentration
and basal (A), maximal insulin stimulation (B), and fold increase (C)
in IR tyrosine phosphorylation. F, subjects with normal glucose toler-
ance; E, subjects with impaired glucose tolerance; and ‚, subjects with
type 2 diabetes.
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thus reflect high basal IR tyrosine kinase activity and be
compatible with our data. In addition, high IR tyrosine
phosphorylation in the basal state has been associated
with fasting hyperinsulinemia in an animal model (21).
Previously, we have shown that fasting hyperinsulin-
emia is associated with low plasma adiponectin concen-
tration (8). Here we report a negative correlation between
basal IR tyrosine phosphorylation and plasma adiponectin
concentration. We hypothesize that adiponectin decreases
basal phosphorylation by promoting insulin signaling
downstream of the IR. This might result in increased
insulin sensitivity and decreased fasting plasma insulin
concentration. Therefore, when adiponectin concentration
is low, fasting hyperinsulinemia, which is associated with
decreased insulin sensitivity, may increase basal phos-
phorylation of the IR. Moreover, we found a relationship
between adiponectin and basal phosphorylation indepen-
dent of fasting plasma insulin, suggesting that factors
other than insulin, such as tumor necrosis factor- (25),
may be determinants of basal tyrosine phosphorylation.
Skeletal muscle insulin-stimulated IR tyrosine phos-
phorylation is an important step in the insulin-signaling
cascade and has been shown to decrease with increasing
insulin resistance (12). In addition, we have previously
shown that the degree of insulin-stimulated phosphoryla-
tion of immunocaptured IR correlated strongly with its
kinase activity (12). Impaired skeletal muscle tyrosine
kinase activity has been shown in obesity and type 2
diabetes (26–28) and has been suggested to be an early or
primary event in the development of insulin resistance. In
our study, subjects with a high basal skeletal muscle
tyrosine phosphorylation of the IR also have the lowest
fold increase in tyrosine phosphorylation upon insulin
stimulation. This may suggest that the relationship be-
tween the fold increase in phosphorylation and plasma
adiponectin concentration may be a function of basal
phosphorylation.
We also investigated whether a low plasma adiponectin
concentration at baseline has an effect on future changes
in whole-body insulin sensitivity. We found that a low
fasting plasma adiponectin concentration at baseline is
associated with a decrease in insulin sensitivity, indepen-
dently of changes in percent body fat. Thus, the presented
results extend our previous observation of a close associ-
ation between hypoadiponectinemia and insulin resistance
(8) by indicating that a low plasma adiponectin concen-
tration precedes the decline in insulin sensitivity. Possible
mechanisms for the insulin-sensitizing effects of adiponec-
tin other than its direct effect on skeletal muscle IR
tyrosine phosphorylation may include increased lipid oxi-
dation in muscle (29) and enhancement of hepatic insulin
action (30), possibly also by interaction with insulin sig-
naling.
In summary, our cross-sectional data suggest a role of
physiological concentration of fasting plasma adiponectin
in the regulation of skeletal muscle IR tyrosine kinase
activity in humans. Prospectively, low plasma adiponectin
concentration at baseline precedes a decrease in insulin
sensitivity. Our data indicate that adiponectin plays an
important role in regulation of insulin sensitivity in humans.
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